Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Wong
Eric T
ET
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D017321:Clinical Trials, Phase I as Topic / Q000592:standards / Q000706:statistics & numerical data; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D006402:Hematologic Diseases / Q000139:chemically induced* / Q000503:physiopathology; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D008223:Lymphoma / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D020714:Maximum Tolerated Dose; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D000069283:Rituximab; D000077204:Temozolomide; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000069283:Rituximab; D003606:Dacarbazine; D000077204:Temozolomide